SAGE News and Press, Sage Therapeutics Inc. From 05/03/22

Sage Therapeutics, Inc. (SAGE) Q1 2022 Earnings Conference Call May 03, 2022 08:00 AM ET Company Participants Helen Rubinstein - Investor Relations Barry Greene - Chief Executive Officer Jim Doherty - Chief Development Officer Kimi Iguchi - Chief Financial Officer Chris Benecchi - Chief Comme...

The following slide deck was published by Sage Therapeutics, Inc. in conjunction with their 2022 Q1 earnings call. For further details see: Sage Therapeutics, Inc. 2022 Q1 - Results - Earnings Call Presentation

Sage Therapeutics press release (NASDAQ:SAGE): Q1 GAAP EPS of -$2.07 misses by $0.04. Revenue of $1.58M (flat Y/Y) misses by $1.65M. For further details see: Sage Therapeutics GAAP EPS of -$2.07 misses by $0.04, revenue of $1.58M misses by $1.65M

Rolling NDA submission for zuranolone in MDD underway, with full submission expected to be completed in the second half of 2022, associated NDA submission in PPD planned for early 2023 Topline data from Phase 3 SKYLARK Study evaluating 50 mg zuranolone for PPD on track for mid...

Sage Therapeutics (NASDAQ:SAGE) is scheduled to announce Q1 earnings results on Tuesday, May 3rd, before market open. The consensus EPS Estimate is -$2.00 (-22.0% Y/Y) and the consensus Revenue Estimate is $3.23M (+104.4% Y/Y). Over the last 1 year, SAGE has beaten EPS estimates 50% of the ti...

Stock Market Today Mid-Morning Updates On Monday, the Dow Jones Industrial Average is up by 50 points as we begin the month of May. The Nasdaq in particular, had one of its worst monthly performance last month since 2008. This comes as investors continue to digest both economic ...

Sage Therapeutics (NASDAQ:SAGE) and Biogen (NASDAQ:BIIB) began a rolling submission of a new drug application (NDA) with the U.S. Food and Drug Administration (FDA) for approval of zuranolone to treat major depressive disorder (MDD). The companies said zuranolone is an investigational tw...

The companies expect to complete submission of the NDA for treatment of MDD in the second half of 2022; associated filing for postpartum depression anticipated in the first half of 2023 Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) initiated a rolling...

Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that it will host a live webcast on Tuesday, May 3, 2022 at 8:00 a.m. ET to announce first quarter 2022 financial results and discuss recent bu...

Wall Street ended a two-day losing streak on Friday, as a late-day push allowed the major U.S. equity indices to finish a choppy session with gains. Amid a solid jobs report and an inverted yield curve, investors considered whether the rally that marked most of late March could resume in the ...